Vitamin Market Outlook For 2008
This article was originally published in PharmAsia News
Executive Summary
In 2007, vitamin products-calcium pantothenate, folic acid, vitamins A, B2, and C-experienced high price increase. Analysts attribute the hike to the monopoly enjoyed by major companies, as well as the inflated cost of raw materials. However, observers do not expect vitamin products to continue enjoying such strong growth in 2008; the temporary price spike was caused by increased costs in infrastructure, environmental management, raw materials and labor. Mostly, vitamin prices hover around cost, and more competitors entering the market will add to the depression. Last year's adjustment of export tax rebates have adversely impacted many sectors; the clamp-down on high-energy, high-polluting industries will further curtail the development of many companies, including those producing vitamins. (Click here for more - Chinese Language)
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.